Short-Term Outcomes of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass for Morbid Obesity
10.17476/jmbs.2020.9.2. 1
- Author:
Young Gil JO
1
;
Jeong Hyun YUEM
;
Jong Min KIM
;
Sung Il CHOI
Author Information
1. Department of Surgery, Kyung Hee University Hospital at Gangdong, Seoul, Korea
- Publication Type:Original Articles
- From:Journal of Metabolic and Bariatric Surgery
2020;9(2):61-67
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This study aimed to evaluate the safety and feasibility of laparoscopic sleeve gastrectomy with duodenojejunal bypass (SDJB) surgery in Korean patients.
Materials and Methods:This was a retrospective study analyzing SDJB surgery with a 200-cm biliopancreatic limb; the surgery was performed between January 2019 and August 2020 in 56 Koreans with morbid obesity. All demographic, clinical, operative, and follow-up data were documented and analyzed for weight loss and diabetes remission efficacy. Safety and feasibility were analyzed in terms of perioperative and postoperative complications. A decrease in the HbA1c value and discontinuation or reduction of anti-diabetics were considered as indicators of improvement in diabetes.
Results:The median operation time was 180.0 min (105-210 min), and the median postoperative hospital stay was 5.0 days (3-35 days). Postoperative complications occurred in two patients who were managed by conversion to Roux-en-Y gastric bypass surgery. Meaningful weight loss was 3.5%, 27.7%, and 54.9% at the 1-month, 3-month, and 6-month follow-ups, respectively. Of the 56 patients, 46 had type 2 diabetes. Among those patients, at the 1-month follow-up, 4/31 patients (12%), at the 3-month follow-up, 22/41 patients (53.6%), and at the 6-month follow-up, 31/42 patients (73.8%) were found to show improvement. Of the patients who received anti-diabetics or insulin therapy, only three (9%) patients continued to receive reduced treatment of diabetes, and the other thirty (91%) discontinued the anti-diabetics.
Conclusion:SDJB surgery with a 200-cm biliopancreatic limb was a safe and effective procedure to treat morbid obesity and diabetes.
